Concordance of Key Actionable Genomic Alterations as Assessed in Tumor Tissue and Plasma in Non Small Cell Lung Cancer

TerminatedOBSERVATIONAL
Enrollment

140

Participants

Timeline

Start Date

April 30, 2016

Primary Completion Date

July 1, 2018

Study Completion Date

June 19, 2019

Conditions
Non Small Cell Lung Carcinoma
Trial Locations (22)

4

St. Vincent's University Hospital, Dublin

13915

Hôpital Nord, Marseille

23114

Bon Secours Cancer Institute, Midlothian

31201

Central Georgia Cancer Care, Macon

33000

Polyclinique Bordeaux Nord Aquitaine, Bordeaux

33011

Hospital Universitario Central Asturias, Oviedo

38138

West Clinic, Germantown

41013

Hospital Universitario Virgen del Rocio, Seville

44718

Gabrail Cancer Center, Canton

50009

Hospital Clinico Universitario Lozano Blesa, Zaragoza

55407

Virginia Piper Cancer Institute, Minneapolis

63011

Centre Jean Perrin, Clermont-Ferrand

90277

Cancer Care Associates d/b/a Torrance Memorial Physician Network, Torrance

98405

MultiCare Health System, Tacoma

7500691

Instituto Nacional del Torax, Santiago

7500836

Fundación Arturo López Perez, Santiago

7650551

Clinica Alemana de Santiago, Santiago

07109

Essex Oncology of North Jersey, Belleville

07753

Meridian Hospitals, Neptune City

160-0023

Tokyo Medical University Hospital, Tokyo

104-0045

National Cancer Center, Tokyo

CH63 4JK

Clatterbridge Cancer Center NHS Foundation Trust, Bebington

Sponsors
All Listed Sponsors
lead

Genomic Health®, Inc.

INDUSTRY

NCT02762877 - Concordance of Key Actionable Genomic Alterations as Assessed in Tumor Tissue and Plasma in Non Small Cell Lung Cancer | Biotech Hunter | Biotech Hunter